期刊文献+

拓扑替康对人肝癌BEL-7402细胞体外迁移、黏附的影响 被引量:1

Effect of topotecan on migration and adhesion of human hepatoma BEL-7402 cells in vitro
下载PDF
导出
摘要 目的研究拓扑替康(topotecan,TPT)对人肝癌BEL-7402细胞体外迁移、黏附的影响。方法体外培养人肝癌BEL-7402细胞,分为实验组和空白组,实验组分为三个亚组,分别用0.1、0.2、0.3 mmol/L的TPT进行干预,空白组给予不含TPT的培养液。采用划痕实验和Transwell小室迁移实验检测TPT对BEL-7402细胞体外迁移能力的影响,采用黏附实验检测TPT对BEL-7402细胞黏附和异质黏附能力的影响。结果0.2、0.3 mmol/L TPT组中BEL-7402细胞的体外迁移能力受到抑制,同质黏附能力增强,而异质黏附能力减弱,差异具有统计学意义(P均<0.05)。结论拓扑替康可抑制肝癌BEL-7402细胞的迁移和异质黏附能力,增强肝癌细胞的同质黏附能力。 Objective To study the effects of topotecan (TPT) on migration and adhesion of the human hepatoma cell line BEL-7402 cells in vitro. Methods The human hepatoma cell line BEL-7402 cells were cultured in vitro, and divided into two groups: experimental group and control group. The experimental group was divided into three subgroups and treated with 0.1, 0.2 and 0.3 mmol/L TPT respectively. The control group was treated with culture medium without TPT. Effects of TPT on ability of migration of BEL-7402 cells was detected by wound-healing assay and Transwell chamber model. Effects of TPT on ability of homogeneous and heteroge- neous adhesion of BEL-7402 cells was assessed by adhesion experiments. Results The ability of migration and heterogeneous adhesion were significantly depressed in 0.2 and 0.3 mmol/L TPT group (P〈0.05). The ability of homogeneous adhesion was effectively enchanced after treated with 0.2 and 0.3 mmol/L TPT (P〈0.05). Conclusion TPT can depress the migratory and heterogeneous adhesion potentials, and it can enchance the homogeneous adhesion potential of the human hepatoma cell line BEL-7402 cells in vitro.
出处 《肝胆胰外科杂志》 CAS 2014年第1期51-54,共4页 Journal of Hepatopancreatobiliary Surgery
关键词 拓扑替康 肝癌 迁移 黏附 topotecan hepatic carcinoma migration adhesion
  • 相关文献

参考文献12

  • 1陈建国,张思维,陈万青.中国2004--2005年全国死因回顾抽样调查肝癌死亡率分析[J].中华预防医学杂志,2010,44(5):383-389. 被引量:82
  • 2汤钊猷.提高肝癌疗效的我见[J].中华肝胆外科杂志,2010,16(8):561-562. 被引量:22
  • 3Rapisarda A, Uranchimeg B, Sordetro DA, et al. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mecha- nism and therapeutic implications [J]. Cancer Res, 2004, 64 (4): 1475-1482.
  • 4Beppu K, Nakamura K, Linehan WM, et al. Topotecan blocks hypoxia-inducible factor-1 alpha and vascular endothelial growth factor expression induced by insulin-like growth fac- tor-I in neuroblastoma cells [J]. Cancer Res, 2005, 65(11): 4775-4781.
  • 5Pencreach E, Guerin E, Nicolet C, et al. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia- inducible factor-lc axis [J]. Clin Cancer Res, 2009, 15(4): 1297-1307.
  • 6Von PaweI J, Schiller JH, Shepherd FA, et al. Topotecan ver- sus cyclophosphamide, doxorubicin, and vincristine for thetreatment of recurrent small-cell lung cancer [J]. J Clin Oncol, 1999, 17(2): 658-667.
  • 7Rothenberg ML. Topoisomerase I inhibitors: review and up- date [J]. Ann Oncol, 1997, 8(9): 837-855.
  • 8方伟岗.恶性肿瘤转移早期检测的挑战与策略[J].中华检验医学杂志,2005,28(5):465-467. 被引量:16
  • 9熊高风,彭景楩.肿瘤细胞侵袭研究进展[J].生理科学进展,2008,39(1):33-36. 被引量:6
  • 10Fejerskov O, Josephsen K, Nyvad B. Surface ultrastructure ofunerupted mature human enamel [J]. Caries Res, 1984, 18(4): 302-314.

二级参考文献73

共引文献149

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部